Kornimate/medical-research-clean huggingface dataset:
effects on nf-κb activity: high dose simvastatin versus combination therapy with ezetimibe

Conditions: Type 2 Diabetes; Inflammation

Summary: lowering ldl cholesterol by statins has been proven to be associated with reduction of proinflammatory regulators e.g. activation of the transcription factor nf-ĸb. up to now the effects of newer cholesterol lowering agents such as ezetemibe with respect to their anti-inflammatory potential are less intensively studied. therefore the investigators analyzed whether equipotent ldl-lowering therapy with simvastatin alone and in combination with ezetimibe have comparable effects on nf-ĸb-activation in peripheral blood mononuclear cells (pbmcs) of patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * 35 to 80 years old * type 2 diabetes * hba1c value between 6.0 % and 9.0 % * elevated ldl-c values \> 100 mg/dl with no lipid lowering treatment within the last six month exclusion criteria: * refused informed consent
case report in complications after laparoscopic transabdominal preperitoneal groin hernia repair using liquibandfix8®

Conditions: Groin Hernia

Summary: this an a case report about management and proving the strenght and resistance of liquibandfix8® using for peritoneal closure in a laparoscopic transabdominal preperitoneal groin hernia repair. the patient had anticoagulation due to a mechanical valvula and postoperatively the patient developed a huge hematoma extraperitoneally. relaparoscopy war performed to identify the problem and check the peritoneal closure.

this an a case report for proving the strenght and resistance of liquibandfix8® using for peritoneal closure in a laparoscopic transabdominal preperitoneal groin hernia repair (tapp). the patient had anticoagulation due to a mechanical valvula and postoperatively after tapp the patient developed a huge hematoma extraperitoneally. the investigatorsperformed relaparoscopy for diagnostic and therapeutic reasons to check stop the bleeding and control the integrety of the peritoneal closure.

Eligibility criteria:
inclusion criteria: * retrospective case report of one patient undergoing laparoscopic groin hernia repair exclusion criteria: - not applicable (retrospective)
predictive models of readmission in heart failure

Conditions: Heart Failure

Summary: this is a prospective nested case-control study. our goals are to create predictive models to readmissions for heart failure and also to define profiles for patients who are readmitted during the first month after the index episode. patients who will be admitted in five hospitals in spain by the reason of a heart failure will be recruited during 18 months. those who will be readmitted in a hospital up to a month after the index episode will be considered cases. controls will be selected from the initial cohort of hospitalized patients.

objective: to create models for predicting the risk of readmission short term (30-90 days) and medium term (one year).to identify differences between patients readmitted and not readmitted, and profiles of frequently preventable readmissions in our setting. methodology: observational prospective cohort of patients who are discharged with a diagnosis of heart failure in 5 participating centers. further, a nested case-control will be developed in the previous cohort, being cases those readmitted and controls will be chosen according to age, sex, etiology of heart failure, comorbidities and functional status. sociodemographic, clinical and health related quality of life, empowerment and baseline self-efficacy as predictors of readmission were collected. regarding the cases and controls, the quality of life in post-discharge transitional period, empowerment and self-efficacy, caregiver burden, social support, discharge care model, use of health services and adequation, conciliation and adherence to treatment will be assessed . cox proportional hazards models will be created, and conditional logistic regression models to identify differences between cases and controls. expected results: national health system will be provided with tools for predicting the risk of readmission useful to clinicians and managers to offer discharge individualized care. the most common characteristics of readmissions and preventable readmissions will be identified, which will be helpful to create specific actions in the future.

Eligibility criteria:
inclusion criteria: * patients admitted by acute heart failure (de novo and acute decompensated) (international classification of diseases, ninth revision, clinical modification: 428.x; some of the 402.x group), older tan 18 who will accept to participate. exclusion criteria: * patients who develop hf episodes during admission, if have been admitted for another reason, * patients transferred from other health centers, * myocardial infarction or stroke in the 4 weeks prior to admission, * life expectancy less than one year, for hf at the terminal or cause different from the ci according to the assessment of the study subjects, * inability to complete the questionnaires or with assistance external (reviewer, family, social) because of sensorineural reason, dementia or ignorance of the language.

Keywords: heart failure readmission predictive models
observation study of prednisone and cyclosporine in treatment of thrombocytopenia in hepatitis b cirrhosis

Conditions: Thrombocytopenia; Hepatitis B; Cirrhosis

Summary: to compare the safety and efficacy of 12 months of low dose prednisone with low dose cyclosporine combined with entecavir in patients with thrombocytopenia associated with hbv-related cirrhosis.


Eligibility criteria:
inclusion criteria: * diagnosed hbv-associated cirrhosis * had an serum hbv dna level of more than 500 iu per milliliter * have compensated liver cirrhosis * thrombocytopenia (defined as a platelet count of \<30,000 per cubic millimeter) * accompanied with bleed tendency (including petechial, episxias, ecchymosis, hemoptysis, hematemesis and hematochezia) * have a liver-biopsy specimen indicative of cirrhosis, ultrasonography and/or computed tomographic imaging evidence of cirrhosis, or endoscopic evidence of portal hypertension(splenomegaly, ascites, and esophageal varicose) exclusion criteria: * pregnant * hepatocellular carcinoma * decompensated cirrhosis * coagulation function abnormal * had a history of other disease (e.g. aplastic anemia, autoimmune disease, idiopathic thrombocytopenia et al) that could induced thrombocytopenia * co-infected with the human immunodeficiency virus * co-infected with hepatitis c virus * co-infected with hepatitis d virus * had a coexisting serious medical or psychiatric illness * serum creatinine level was more than 1.5 times the upper limit of the normal range
san raffaele eoe biobank

Conditions: Eosinophilic Esophagitis

Summary: eosinophilic esophagitis (eoe) is a immuno-mediated disease, characterised by a th-2 food-antigen driven chronic inflammatory response of the esophagus. main symptoms are dysphagia and food bolus impaction, frequently overlapping with most atypical and general symptoms like heartburn or regurgitation and difficulty to thrive in children. overall incidence and prevalence of eoe are rapidly increasing. the complete comprehension of pathogenetic and molecular mechanism underlying this complex and relatively new disease is still to be conquered. for this reason, we created this eoe biobank, in order to collect blood, oral and esophageal tissue samples of proven eoe patients to further exploit new insights of this disease.

every eoe patient pertaining to the eoe unit of san raffaele hospital in milan from 1st june 2023 will be enrolled in the eoe biobank protocol after being adequately informed and after having signed the informed consent during a preliminary visit where also different clinical and demographic variable of each patient will be taken and stored in an anonymus database. every patient, during the endoscopic examination performed according to clinical practice guideline for his management, will be asked to provide a sample of oral saliva, 5 ml of blood sample (directly withdraw from the previously placed venous catheter) and additional esophageal biopsies from the esophagus, normally performed for the diagnosis or the follow-up of the disease. the collected samples will be stored in biological resources centre (brc) of the host organization. these sample will later be analyzed "in vitro" in the context of dedicated protocols

Eligibility criteria:
inclusion criteria: * eoe diagnosis proven histologically with clinical activity * age \> 16 years exclusion criteria: * not signed informed consent * no definite eoe diagnosis

Keywords: eosinophilic disorders translational
diagnostic value of kl-6 in ild

Conditions: Pulmonary Fibrosis

Summary: kl-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-asian populations. therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication. hypothesis kl-6 may be a useful biomarker in the management of interstitial lung diseases. but it is necessary to know more about its utility in the european population. study objectives: * to determine the concentration of kl-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis * diagnostic yield of kl-6 in patients with pulmonary fibrosis. * correlation of kl-6 values with functional and radiological parameters of disease severity at diagnosis. * correlation of serum kl-6 values with the evolution of the disease.


Eligibility criteria:
inclusion criteria: 1. subjects older than 18 years. 2. chronic respiratory diseases )including fibrotic interstitial lung disease, asthma or copd) related or not to a connective tissue disease. 3. acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits. exclusion criteria: 1. absence of informed consent 2. psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).
routine versus selective protamine administration to reduce bleeding complications after transcatheter aortic valve implantation (popular ace tavi)

Conditions: Aortic Valve Stenosis

Summary: heparin reversal by protamine administration after transcatheter aortic valve implantation (tavi) may reduce bleeding events. however, protamine can also cause life-threatening allergic reactions. high-quality evidence regarding the clinical safety and efficacy of routine protamine administration after tavi is lacking. the aim of this clinical trial is to determine if routine protamine administration, compared with selective protamine administration, reduces the risk of cardiovascular mortality or bleeding within 30 days after transcatheter aortic valve implantation.


Eligibility criteria:
inclusion criteria: * aged \> 18 years * undergoing transfemoral tavi with any commercially available transcatheter heart valve * provided written informed consent exclusion criteria: * documented protamine allergy or anaphylaxis * recent pci (\< 3 months before tavi) * planned arterial access via surgical cut-down * pregnancy

Keywords: tavi tavr bleeding mortality allergy protamine
rhythmic stimulus effects on neuronal oscillatory activity and speaches capabilities in deaf children

Conditions: Children Deafness

Summary: the deaf children showed deficits in speech processing and temporality. they badly apprehend temporal concepts and perceptions of deficit so the acoustic phenomena marking the time course linguistically. their prediction capabilities and anticipation multisensory events are thereby affected, thus impacting their ability to adapt to multiple and complex interaction possibilities that arise during a conversation.the project aim it is to measure the impact of a musical rhythmic stimulation of neuronal activity and the temporal prediction capabilities of older deaf children 5 to 8 years and its impact on their language skills in a conversational task. a matched control group of age will be examined for each of the proposed tasks. we first measure the capacity to anticipate a situation of language interaction. for this purpose, we will use an alternate naming paradigm with a virtual partner, already developed and tested in children with normal hearing. this paradigm approaches the conversational situation while allowing control of the time parameter of speech (speed of trade) and by controlling the bias (temporal) inherent linguistic programming difficulties of children in a spontaneous conversation situations . then we will couple behavioral measurements with measurements of eye movements and the electroencephalogram (eeg) in deaf children. for this, we use a dialog observation task already developed for normal hearing children. this task will allow us firstly to analyze the anticipation level of speaking turns by analyzing eye movements (which "precedes" the speaker). secondly, it will allow us to study the effects of manipulation of the acoustic parameters of auditory evoked potentials (aep) and the oscillatory activity of the motor system (eeg, mu rhythm and beta). the audiomoteur coupling would seem to be the key point of anticipatory processes and convergence in conversational interaction will also be studied using cortico-cortical coherence techniques to assess the dynamics of connectivity between remote networks (system here auditory and motor system).


Eligibility criteria:
inclusion criteria: * prélingual paired deaf or implanted cochlear children. exclusion criteria: * childreen with other major disabilities and associated disorders. * clidren with failure to understand instructions either directly oral or sign language.
a compassionate access protocol to assess the safety of xolairtm (omalizumab) in patients (≥ 6 years old) with severe allergic asthma who remain symptomatic despite optimal therapy

Conditions: Asthma

Summary: this study has the objective of providing compassionate use access to omalizumab (xolair) and to evaluate the safety of xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to gina step 4 treatment guidelines.


Eligibility criteria:
inclusion criteria: * male or female, ≥ 6years of age; * who have a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria; * severe persistent allergic asthma who remain symptomatic despite optimal therapy (as per canadian asthma consensus report (1999)); * subjects having successfully completed one of the following protocols: cige025a011e3, cige025a2425, cige025aia05; * elevated immunoglobin e levels exclusion criteria: * significant systemic disease * pregnancy or lactation * an active lung disease other than allergic asthma (eg: cystic fibrosis, bronchiestasis); * history of food or drug related severe anaphylactoid or anaphylactic reaction(s); * current treatment with warfarin (coumadin®), immunomodulatory therapy (e.g., methotrexate, gold, cyclosporine), or antiplatelet therapy.

Keywords: asthma, anti-immunoglobin e, omalizumab
the effect of oral care protocol on prevention of oral mucositis in pediatric cancer patients

Conditions: Mucositis; Pediatric Cancer; Oral Cavity

Summary: this study conducted to determine the effects of two oral care protocols containing sodium bicarbonate or saline solution in the prevention of oral mucositis (om), mucositis degree, and recovery time in children with cancer.

the study conducted as a randomized controlled trial with a parallel design with two groups; study group/ oral care protocol with saline solution control group/ oral care protocol with sodium bicarbonate solution study hypothesis; there is a difference in oral mucositis (om) between groups. there is a difference in the degree of om between groups. there is a difference in the om recovery time between groups. there is a difference in demographic variables in patients with and without mucositis. the study sample was comprised of 43 children with cancer aged 1-17 years, received chemotherapy for ≥3 days at inpatient clinics, and whose families agreed to their participation in the study. patients excluded who have oral ulceration or mucositis, taking any antiviral or antifungal therapy for om before enrollment in the study. this trial was a triple blinded which the patients/parents, nurses, and the investigators have no idea about the groups. in the study, patients were allocated by the blocked randomization. after naturally separating the gender variable into 2 layers, the age was divided into 5 layers as "\ 3-6 years, 6-12 years,\>12 years", and the diagnosis variable was divided into 3 layers as "all, aml and oncological tumors." socio-demographic data collection form, international child mucositis rating scale (chimes), and mucositis follow-up form used. the child who do not have mucositis and who will be hospitalized for more than 3 days for chemotherapy will be distributed to the groups by stratified randomization method, the information of the patients will be obtained with the sociodemographic data collection form, oral care training will be given to the patient and the family, oral care protocol will be applied and it will be evaluated daily with the chimes and mucositis follow-up form, and the severity of mucositis according to the world health organization mucositis assessment index, the mean score of the chimes, recovery time will be monitored through the mucositis follow-up form.

Eligibility criteria:
inclusion criteria: * have cancer, aged 1-17 years, received chemotherapy for ≥3 days at inpatient clinics and whose families agreed to their participation in the study. exclusion criteria: * who have oral ulceration or mucositis, in terminal period, taking any antiviral or antifungal therapy for om before enrollment in the study.
elastography in chronic liver disease in children

Conditions: Chronic Liver Disease

Summary: chronic liver disease is a significant health issue among children and it can result in fibrosis, cirrhosis and liver failure. since the prognosis and monitoring of these diseases are different from each other,, conventional ultrasonography is preferred for the investigation of chronic liver diseases in children, as it is non-invasive, cheap, feasible and available. elastography, an ultrasonographic non-invasive procedure that measures tissue stiffness.

chronic liver disease is a significant health issue among children and it can result in fibrosis, cirrhosis and liver failure. since the prognosis and monitoring of these diseases are different from each other, the term chronic liver disease (cld) implies a long standing irreversible change in the hepatic structure that may end in complications like cirrhosis leading to premature death. while liver needle biopsy is still recognised to be the gold standard for the assessment of liver fibrosis in the diagnosis and follow-up of chronic liver diseases, researchers tend to study non-invasive methods in the determination of liver fibrosis, as liver needle biopsy is an invasive, painful and expensive procedure, which can cause possible sampling errors and potential complications , conventional ultrasonography is preferred for the investigation of chronic liver diseases in children, as it is non-invasive, cheap, feasible and available. elastography, an ultrasonographic non-invasive procedure that measures tissue stiffness. liver fibrosis is a result of chronic damage, and attacks and remissions throughout the course of the disease trigger the formation of fibrosis. apart from being a direct indicator of liver damage, fibrosis has an important role in the development of hepatocyte dysfunction and portal hypertension. in a clinical aspect, knowing the state and progress of fibrosis is important in the assessment of treatment response for the severity and the prognosis of the disease. the degree of fibrosis in the liver is important in the determination of prognosis, and management of the process in chronic liver disease. patients with fibrosis benefit from treatment in case of early diagnosis. ultrasound elastography is a non-invasive method.

Eligibility criteria:
inclusion criteria: 1 - all patients referred to the radiology department over the estimated period of the study. 2 - males and /or females from ( 0 to 18 years ) 3 - have clinical or laboratory or histopathological evidence of chronic liver disease 4 - had undergone liver biopsy. exclusion criteria: 1. - patients males and or females older than 18 years 2. - patients who hadn't undergone liver biopsy previously 3. - patients with acute liver disease 4. - patients with human immune- deficiency virus (hiv) co infection. 5. - patients with pacemaker (pm) or implantable cardioverter defibrillator (icd) devices.
a study of jnj-80038114 in participants with advanced stage prostate cancer

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to determine recommended phase 2 dose(s) (rp2ds) of jnj-80038114 in part 1 (dose escalation) and to determine the safety at the rp2d(s) in part 2 (dose expansion).


Eligibility criteria:
inclusion criteria: * metastatic castration-resistant prostate cancer (mcrpc) with confirmed adenocarcinoma of the prostate as defined by prostate cancer working group 3 (pcwg3) * measurable or evaluable disease * at least 1 prior treatment for mcrpc * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate organ functions as defined by certain laboratory values * must sign an informed consent form (icf) * participants must agree to use a highly effective form of birth control as guided by the study doctor exclusion criteria: * concurrent anticancer therapy * severe or long-lasting side effects related to prior anticancer therapy * known allergies to jnj-80038114 or its excipients * brain metastasis or known seizure history * significant infections or lung, heart or other medical conditions

Keywords: prostate cancer
rtms treatment of primary progressive aphasia

Conditions: Primary Progressive Aphasia; Repetitive Transcranical Magnetic Stimulation

Summary: primary progressive aphasia (ppa) is a neurodegenerative disease in which language function is gradually and progressively impaired. patients will eventually be disabled in communication and have cognition deficits, which put a heavy burden not only on their families but also on the whole society. however, no effective treatment for ppa has been explored so far. the current clinical randomized trial is to study the safety and efficacy of repetitive transcranial magnetic stimulation (rtms) for the treatment of ppa. also, multi-modality of neuroimaging techniques, such as functional mri and pet will be used to investigate brain network changing in this procedure.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ppa exclusion criteria: * scored below 15 on the mini-mental state exam (mmse) * history of seizures or unexplained loss of consciousness * pregnancy * surgical breach of the skull * mri contraindication